| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |